Abstract: The present disclosure relates to exosome bone graft systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.

Abstract: The present disclosure relates to exosome systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.

Abstract: The present disclosure relates to exosome bone graft systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.

Abstract: The present disclosure relates to exosome systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.

Abstract: The present disclosure relates to exosome systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.

Abstract: The present disclosure relates to compositions, including, hydrogel compositions useful as topical analgesics including cannabinoids, an effective amount of a compound (e.g., psilocybin/psilocin) for treating drug addiction (e.g. opioid addiction) and menthol where the menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid. The present disclosure also disclosure relates to compositions, including, hydrogel compositions useful as topical analgesics including cannabinoids and menthol as well as carboxymethyl cellulose, carrageenan and a cross-linking agent.

Abstract: The present disclosure relates to exothermic nose strip devices and compositions, including, methods of making and using them.

Abstract: The present disclosure relates to compositions, methods of use and methods of manufacturing of transdermal delivery systems, patches, vehicles and devices including an iontophoretic transdermal delivery system, patch, vehicle or device used to relieve pain (i.e., analgesics) and/or inflammation that contain a pharmaceutically effective amount of a pharmaceutically acceptable and effective cannabinoid and menthol.

Abstract: The present disclosure relates to exosome systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.

Abstract: The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas. wherein A is —(CH2)a—CH?CH—(CH 2)5-a—H where a is from 0 to 5, —(CH2)b—CH?CH—(CH 2)6-b—H where b is from 0 to 6, —(CH2)c—CH?CH—(CH 2)7-c—H where c is from 0 to 7, —(CH2)d—CH?CH—(CH 2)8-d—H where d is from 0 to 8, or —CH2)e—CH?CH—(CH 2)9-d—H where d is from 0 to 9; B is hydrogen or C1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

Abstract: The present disclosure relates to exosome systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.

Abstract: The present disclosure relates to compositions, methods of use and methods of manufacturing of a transdermal delivery systems, patches, vehicles and devices used to relieve pain (i.e., analgesics) and/or inflammation that contain a pharmaceutically effective amount of a pharmaceutically acceptable and effective cannabinoid and menthol.

Abstract: The present disclosure relates to compositions, methods of use and methods of manufacturing of a transdermal delivery systems, patches, vehicles and devices used to relieve pain (i.e., analgesics) and/or inflammation that contain a pharmaceutically effective amount of a pharmaceutically acceptable and effective cannabinoid and menthol.

Abstract: The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas. wherein A is —(CH2)a—CH?CH—(CH 2)5-a—H where a is from 0 to 5, —(CH2)b—CH?CH—(CH 2)6-b—H where b is from 0 to 6, —(CH2)c—CH?CH—(CH 2)7-c—H where c is from 0 to 7, —(CH2)d—CH?CH—(CH 2)8-d—H where d is from 0 to 8, or —CH2)e—CH?CH—(CH 2)9-d—H where d is from 0 to 9; B is hydrogen or C1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

Abstract: A fabric is saturated with a salt solution, such that when an electric current is applied to the fabric, the fabric exhibits a bactericidal ability. In another aspect, a salt solution includes a conductor, a humectant, a solvent, and a binder, where the conductor has an NaCl % w/w of between 3 and 11, the humectant has a glycerol % w/w of between 3 and 15, the solvent has a water % w/w of between 77 and 89 and the fixative includes a binder % w/w of between 0.01 and 2.0.

Abstract: The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas. wherein A is —(CH2)a-CH?CH—(CH 2)5-a-H where a is from 0 to 5, —(CH2)b-CH?CH—(CH 2)6-b-H where b is from 0 to 6, —(CH2)c-CH?CH—(CH 2)7-c-H where c is from 0 to 7, —(CH2)d-CH?CH—(CH 2)8-d-H where d is from 0 to 8, or —CH2)e-CH?CH—(CH 2)9-d-H where d is from 0 to 9; B is hydrogen or C1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

Abstract: The present disclosure relates to exosome bone graft systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.

Abstract: The aspects of the disclosed embodiments relate to exosome systems and compositions and preservative systems and compositions including systems and compositions including diatomic oxygen as well as methods of use and methods of manufacturing of them.

Abstract: The present disclosure relates to exosome systems and compositions and preservative systems and compositions including systems and compositions including diatomic oxygen as well as methods of use and methods of manufacturing of them.

Abstract: The present disclosure relates to exosome systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.